Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 19/20 | 0.80 |
| ▸ | MMP3 | P08254 | 11/20 | 0.80 |
| ▸ | MMP1 | P03956 | 1/20 | 0.72 |
| ▸ | MMP7 | P09237 | 1/20 | 0.72 |
| ▸ | MMP13 | P45452 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30627068 | 1.00 | MMP8 (0.80) | MMP8MMP3MMP1MMP7MMP13 | |
| SCHEMBL208179 | 1.00 | MMP8 (0.80) | MMP8MMP3MMP1MMP7MMP13 | |
| SCHEMBL29697336 | 1.00 | MMP8 (0.80) | MMP8MMP3MMP1MMP7MMP13 | |
| SCHEMBL6010103 | 0.89 | MMP8 (1.00) | MMP8MMP3MMP1MMP7 | |
| SCHEMBL5098064 | 0.87 | POLB (0.72) | MMP8MMP3 | |
| SCHEMBL13856619 | 0.87 | POLB (0.72) | MMP8MMP3 | |
| SCHEMBL26616322 | 0.87 | POLB (0.72) | MMP8MMP3 | |
| SCHEMBL31685843 | 0.87 | POLB (0.72) | MMP8MMP3 | |
| SCHEMBL8383233 | 0.87 | POLB (0.72) | MMP8MMP3 | |
| SCHEMBL6010109 | 0.87 | MMP8 (1.00) | MMP8MMP3MMP1MMP7MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | claimed |
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9523090-B2 | Compositions and methods for treating inflammation | REVALESIO CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-8828977-B2 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2605013-A1 | Stimulation of pancreatic beta-cell proliferation | THE ROCKEFELLER UNIVERSITY (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION | 2012-05-10 | — | — | US | disclosed |
| WO-2010062628-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2006133333-A2 | STIMULATION OF PANCREATIC B CELL PROLIFERATION | THE ROCKEFELLER UNIVERSITY (US) | 2006-12-14 | — | — | WO | disclosed |
| US-6861504-B2 | Compounds and methods for the modulation of CD154 | CBR, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050019743-A1 | Compounds and methods for improving platelet recovery and function | CENTER FOR BLOOD RESEARCH, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004105837-A2 | COMPOUNDS AND METHODS FOR IMPROVING PLATELET RECOVERY AND FUNCTION | CENTER FOR BLOOD RESEARCH, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248813-A1 | Compounds and methods for the modulation of cd154 | CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040072750-A1 | Compounds and methods for the modulation of CD154 | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1399466-A2 | COMPOUNDS AND METHODS FOR THE MODULATION OF CD154 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040048803-A1 | Compounds and methods for the modulation of CD154 | PHILLIPS DAVID (US) | 2004-03-11 | — | — | US | disclosed |
| WO-2002089730-A2 | COMPOUNDS AND METHODS FOR THE MODULATION OF CD154 | THE CENTER FOR BLOOD RESEARCH, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020165166-A1 | Compounds and methods for the modulation of CD154 | CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | CHRM3, CHRNG, GRK3 | MMP8 793/4885MMP3 3032/4885MMP1 1698/4885 |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | MMP9, MMP14, MMP10 | MMP8 19/4885MMP3 6/4885MMP1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.